3-(2-氧代-乙基)-哌啶-1-羧酸叔丁酯 | 372159-76-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-(2-氧代-乙基)-哌啶-1-羧酸叔丁酯
• 中文别名: 1-BOC-3--哌啶乙醛；1-Boc-3-哌啶乙醛
• 英文名称: tert-butyl 3-(2-oxoethyl)piperidine-1-carboxylate
• CAS: 372159-76-7
• 化学式: C₁₂H₂₁NO₃
• 分子量: 227.304
• InChiKey: IOZGGOSCHPGERX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2-氧代-乙基)-哌啶-1-羧酸叔丁酯 在 盐酸 、 三乙酰氧基硼氢化钠 作用下， 以 1,4-二氧六环 、 1,2-二氯乙烷 为溶剂， 生成
  参考文献：
  名称：

  CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure–activity relationships

  摘要：

  CCR3 antagonist leads with IC50 values in the muM range were converted into low nM binding compounds that displayed in vitro inhibition of human eosinophil chemotaxis induced by human eotaxin. In particular, 4-benzylpiperidin-1-yl-n-propylureas and erythro-3-(4-benzyl-2-(alpha-hydroxyalkyl)piperidin-1-yl)-n-propylureas (obtained via Beak reaction of N-BOC-4-benzylpiperidine) exhibited single digit nanomolar IC50 values for CCR3. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(02)00206-8
• 作为产物：
  描述：

  3-哌啶甲醇 在 sodium cyanide 、 二异丁基氢化铝 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 26.75h， 生成 3-(2-氧代-乙基)-哌啶-1-羧酸叔丁酯
  参考文献：
  名称：

  [EN] NOVEL HISTONE METHYLTRANSFERASE INHIBITORS
  [FR] NOUVEAUX INHIBITEURS D'HISTONE MÉTHYLTRANSFÉRASES

  摘要：

  本发明涉及式(I)定义的新的化合物。这些化合物是七-β-链家族组蛋白甲基转移酶的抑制剂，特别是KMT9的抑制剂。

  公开号：

  WO2021053158A1

文献信息

• Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
  申请人：Egle Ian

  公开号：US20090192169A1

  公开（公告）日：2009-07-30

  Compounds of Formula I: wherein A, B, D, L, R 1 , R 2 , R 3 , R 4 , m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

  式I的化合物： 其中A、B、D、L、R1、R2、R3、R4、m和n的定义如描述中所定义。本发明还涉及制备这些化合物的方法，以及用于制备的新中间体，含有这些化合物的药物组合物，以及这些化合物在治疗中的应用。
• [EN] AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS<br/>[FR] COMPOSÉS AMIDO-THIOPHÈNE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BÊTA-HSD1
  申请人：UNIV EDINBURGH

  公开号：WO2009074789A1

  公开（公告）日：2009-06-18

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. Formula (I).

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些酰胺噻吩化合物，其中包括抑制11β-羟基类固醇脱氢酶1（11β-HSD1）。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体外和体内抑制11β-羟基类固醇脱氢酶1；治疗通过抑制11β-羟基类固醇脱氢酶1而得到改善的疾病；治疗代谢综合征，其中包括2型糖尿病和肥胖等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质紊乱和心血管疾病，如缺血性（冠状）心脏病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。公式（I）。
• [EN] BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS<br/>[FR] BENZOFUROPYRIMIDINONES EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：EXELIXIS INC

  公开号：WO2009086264A1

  公开（公告）日：2009-07-09

  A compound according to formula I: or a pharmaceutically acceptable salt thereof; wherein R1, R2, R3a, R3b, R3c and R3d are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

  根据公式I的化合物：或其药用可接受盐；其中R1、R2、R3a、R3b、R3c和R3d如规范中所定义，以及其药物组合物和使用方法。
• Pyridine derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US06562811B1

  公开（公告）日：2003-05-13

  Pyridine compounds of general formula: wherein —R1 represents in which R11 is hydrogen, C1-6 alkyl, halogen, hydroxy, C1-12 alkoxy, nitro, amino, C1-6 alkylsulfonylamino, C1-6 alkoxycarbonyl, C1-6 alkylamino, di(C1-6 alkyl)amino, C1-6 alkanoylamino, phenyl C1-6 alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2 represents hydrogen or halogen; R3 represents hydrogen, —CR31R32R33, or —NR34R35; R4 is hydrogen, carbamoyl, CN, carboxyl, etc.; R5 is amino, C1-6 alkylamino, di C1-6 alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.

  通式为的吡啶化合物：其中-R1代表其中R11为氢，C1-6烷基，卤素，羟基，C1-12烷氧基，硝基，氨基，C1-6烷基磺酰胺基，C1-6烷氧羰基，C1-6烷基氨基，二(C1-6烷基)氨基，C1-6烷酰胺基，苯基C1-6烷基氨基，苯基磺酰胺基，或-O-(CH2)n-R111；R2代表氢或卤素；R3代表氢，-CR31R32R33，或-NR34R35；R4为氢，氨基甲酰基，氰基，羧基等；R5为氨基，C1-6烷基氨基，二C1-6烷基氨基等或其盐。该化合物具有出色的抗炎活性和其他生物活性。
• [EN] PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK- beta ) INHIBITING ACTIVITY<br/>[FR] DERIVES DE PYRIDINE AVEC ACTIVITE INHIBITRICE DE L'IKB-KINASE (IKK-KINASE9
  申请人：BAYER AG

  公开号：WO2002024679A1

  公开（公告）日：2002-03-28

  Pyridine compounds of general formula (I) wherein -R1 represents, or in which R11 is hydrogen, C¿1-6? alkyl, halogen, hydroxy, C1-12 alkoxy, nitro, amino, C1-6 alkylsulfonylamino, C1-6 alkoxycarbonyl, C1-6 alkylamino, di (C1-6 alkyl)amino, C1-6 alkanoylamino, phenyl C1-6 alkylamino, phenylsulfonylamino, or -O-(CH2)n-R?111 ; R2¿ represents hydrogen or halogen; R3 represents hydrogen, -CR?31R32R33¿, or -NR?34R35; R4¿ is hydrogen, carbamoyl, CN, carboxyl, etc.; R5 is amino, C¿1-6? alkylamino, di C1-6 alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.

  通式为（I）的吡啶化合物，其中-R1代表，或其中R11为氢，C1-6烷基，卤素，羟基，C1-12烷氧基，硝基，氨基，C1-6烷基磺酰胺基，C1-6烷氧羰基，C1-6烷基氨基，二（C1-6烷基）氨基，C1-6烷酰胺基，苯基C1-6烷基氨基，苯基磺酰胺基，或-O-（CH2）n-R?111; R2代表氢或卤素; R3代表氢，-CR?31R32R33¿，或-NR?34R35; R4为氢，氨甲酰基，氰基，羧基等; R5为氨基，C1-6烷基氨基，二C1-6烷基氨基等或其盐。该化合物具有优异的抗炎活性和其他生物活性。